Insider Trading Activity SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) – CEO Sold 70,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)

Friedhelm Blobel , CEO of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) reportedly Sold 70,000 shares of the company’s stock at an average price of 10.55 for a total transaction amount of $738,500.00 SEC Form

Insider Trading History For SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)

  • On 2/28/2013 Friedhelm Blobel, CEO, bought 3,000 with an average share price of $3.86 per share and the total transaction amounting to $11,580.00.
  • On 8/20/2013 Min Yin, VP, sold 12,500 with an average share price of $5.50 per share and the total transaction amounting to $68,750.00.
  • On 8/22/2013 Min Yin, VP, sold 10,938 with an average share price of $5.50 per share and the total transaction amounting to $60,159.00.
  • On 5/16/2014 Hong Zhao, CEO, sold 12,500 with an average share price of $4.75 per share and the total transaction amounting to $59,375.00.
  • On 8/15/2014 Nancy T Chang, Director, bought 25,040 with an average share price of $6.00 per share and the total transaction amounting to $150,240.00.
  • On 9/2/2014 Lan Xie, CFO, sold 36,468 with an average share price of $6.97 per share and the total transaction amounting to $254,181.96.
  • On 12/11/2014 Richard J Hawkins, Director, sold 15,591 with an average share price of $8.80 per share and the total transaction amounting to $137,200.80.

    • Analyst Ratings For SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
    These are 1 Buy RatingThe current consensus rating for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) is Buy (Score: 3.00) with a consensus target price of $14.00 , a potential (32.70% upside)

    Analyst Ratings History For SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)

    • On 1/6/2015 Aegis Reiterated Rating Positive
    • On 6/29/2015 MLV & Co. Initiated Coverage of rating Buy
    • On 7/9/2015 BWS Financial Downgraded rating Hold to Sell
    • On 11/28/2016 Maxim Group Initiated Coverage of rating Buy with a price target of $14.00

    About SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
    SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

    Recent Trading Activity for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
    Shares of SciClone Pharmaceuticals Inc. closed the previous trading session at 10.55 0.00 0.00% with 387,091 shares trading hands.